Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study
Biomea Fusion Inc‘s (NASDAQ:BMEA) stock price plummeted after the company priced its public offering.
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from BMEA
Is This Growth Stock Under $10 With 370% Upside a Buy Right Now?
This biotech company has some promising candidates in its pipeline. Could this minor setback slow the company's progress?
Barchart ·
Wall Street Expects 190% Upside for This Biotech Stock
It's not just AI stocks that have piqued Wall Street’s attention - analysts also think this biotech stock is set for massive growth, with forecasts calling for the share price to nearly triple over the next 12 months.
Barchart ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Barchart
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
